Back to news

Helus Pharma Announces Positive Topline Results from Phase 3 APPROACH Study evaluating HLP003 as Adjunctive Treatment in Major Depressive Disorder

Globe Newswire•16/11/2026•07:00 ET
0

Key Highlights

  • ➤Week 6 MADRS reduction -7.6 points versus placebo, p<0.0001, effect size 0.653
  • ➤Week 12 MADRS reduction -7.0 points versus placebo, p<0.0001, effect size 0.581
  • ➤Day 2 response rate 50.0% versus 23.6% for placebo, p=0.0002
  • ➤HLP003 generally well tolerated; three treatment-related serious adverse events reported
  • ➤EMBRACE topline results expected in 4Q 2027

Expert Statements

Michael Halstead, Chief Executive Officer of Helus Pharma

“The large unmet need for patients with major depressive disorder who continue to experience persistent symptoms underscores the importance of new rapid-acting and well-tolerated adjunctive treatment options,”

Michael Halstead, Chief Executive Officer of Helus Pharma

“We believe these data demonstrate a therapeutic profile that has the potential to meaningfully improve outcomes for patients and strengthen our momentum as we continue to progress HLP003 toward regulatory approval and potential commercialization.”

Roger S. McIntyre, M.D., FRCPC, Professor of Psychiatry and Pharmacology, University of Toronto

“The results from the APPROACH study set a new benchmark for what may be achievable with adjunctive treatment in major depressive disorder,”

Roger S. McIntyre, M.D., FRCPC, Professor of Psychiatry and Pharmacology, University of Toronto

“The magnitude of benefit observed in this study is highly compelling and has the potential to redefine expectations among clinicians treating patients who continue to experience depressive symptoms while on an anti-depressant.”

HLP003 achieved statistically significant and clinically meaningful results in the primary and key secondary endpoints starting as early as Day 2 and maintained at all time points

-7.6 point placebo-adjusted change from baseline at Week 6 for the primary endpoint on the Montgomery-Asberg Depression Rating Scale (“MADRS”) (p< 0.0001)

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in